Skip to main content
Clinical Trials/NCT01615302
NCT01615302
Unknown
Not Applicable

Use of Platelet Rich Plasma (PRP) as an Adjunct in the Treatment of High Peri-anal Fistulas.

Maastricht University Medical Center6 sites in 1 country120 target enrollmentMarch 2012
ConditionsRectal Fistula

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Fistula
Sponsor
Maastricht University Medical Center
Enrollment
120
Locations
6
Primary Endpoint
Recurrence of fistulas
Last Updated
13 years ago

Overview

Brief Summary

Rationale:

Closure of the internal opening is the most accepted standard procedure in the treatment of peri-anal fistulas. The mucosal advancement flap is considered as golden standard. In one out of the three patients mucosal flap repair fails. Possible causal factors are incomplete clearance of pus and debris, incomplete closure of the internal opening, inappropriate host response in patients with risk factors like smoking or diabetes. Platelet derived growth factors may facilitate closure of the internal opening, especially in patients with impaired wound healing.

Objective:

The use of autologous platelet rich plasma (PRP) as an adjunct to the staged mucosal advancement flap to achieve a better closure rate of complex peri-anal fistula's.

Study design:

Randomized, multicenter trial.

Study population:

Patients with complex cryptoglandular peri-anal fistula's.

Intervention:

Injection of PRP in the curretted fistula track under the mucosal flap.

Main study parameters/endpoints:

  • Recurrence rate
  • Post-operative pain
  • Continence
  • Quality of life.

Nature and extent of the burden and risks associated with participation, group relatedness:

Because autologous blood is used, no extra risk are expected.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
April 2016
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Complex peri-anal fistula.
  • Able to understand informed consent.

Exclusion Criteria

  • Pregnancy
  • Local malignancy
  • Crohn's disease or Ulcerative colitis
  • Traumatic or iatrogenic lesion
  • Thrombocytopenia
  • Splenomegaly
  • Bleeding disorders
  • Hematologic malignancies

Outcomes

Primary Outcomes

Recurrence of fistulas

Time Frame: Assessed up to 104 weeks after operation

The surgeon or docter in the outpatient clinic will decide if there is a recurrent fistula or not. In case of doubt a MRI will be made.

Secondary Outcomes

  • Pain(Assessed at 104 weeks after operation)
  • Quality of Life(Assessed at 16 weeks after operation)
  • Incontinence(Assessed at 104 weeks after operation)
  • Quality of life(Assessed at 104 weeks after operation)

Study Sites (6)

Loading locations...

Similar Trials